Leona Health | $14,000,000 | (Dec 18, 2025)
Limenet | $8,217,860 | (Dec 18, 2025)
Codoxo | $35,000,000 | (Dec 18, 2025)
T-CURX GmbH
Germany
- Würzburg, Bavaria
- 18/12/2025
- Series A
- $20,000,000
T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment.
T-CURX has exclusive licenses for proprietary technologies and CAR-T product opportunities developed in the laboratory of Prof. M. Hudecek, Würzburg, Germany one of the leading European clinical CAR-T cell laboratories.
T-CURX leverages several cutting-edge CAR-T engineering technologies, including virus-free transposon based genetic engineering and a highly flexible and modular CAR format. This provides unparalleled flexibility, efficacy, safety, but also scalability for developing CAR-T cells at significantly lower costs than conventional lentivirus-based CAR-T cell manufacturing.
- Industry Biotechnology Research
- Website https://www.t-curx.com/
- LinkedIn https://www.linkedin.com/company/t-curx/
Drive Health | $15,000,000 | (Dec 18, 2025)
DataLane | $22,500,000 | (Dec 18, 2025)
Addition Therapeutics | $100,000,000 | (Dec 18, 2025)
Scylos | $3,000,000 | (Dec 18, 2025)
Navier AI | $6,500,000 | (Dec 17, 2025)
Verisoul | $8,800,000 | (Dec 17, 2025)
Aeovian Pharmaceuticals | $55,000,000 | (Dec 17, 2025)